



Scriptaid

Catalog No: tcsc1014



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

287383-59-9

Formula:

 $C_{18}H_{18}N_2O_4$

Pathway:

Autophagy; Epigenetics; Cell Cycle/DNA Damage

Target:

Autophagy;HDAC;HDAC

Purity / Grade:

>98%

Solubility:

DMSO : \geq 150 mg/mL (459.63 mM)

Alternative Names:

Scriptide; GCK 1026

Observed Molecular Weight:

326.35

Product Description

Scriptaid is a potent **histone deacetylase (HDAC)** inhibitor, used in cancer research.



IC50 & Target: HDAC^[1]

In Vitro: Scriptaid (1 μ g/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC₅₀s of 0.5-1.0 μ g/mL. Scriptaid (0.1-1.0 μ g/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA, they enhance ER expression and induce a functional ER protein^[1]. Scriptaid and SAHA preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti-*T. gondii* compound with low cytotoxicity, and the IC₅₀ is 39 nM. Scriptaid has atypical effects in T. gondiiinfected HS68 cells^[2]. Scriptaid inhibits the growth of HeLa cells with IC₅₀ of 2 μ M at 48 h in a dose-dependent manner. Scriptaid also affects cell-cycle and apoptosis^[3].

In Vivo: Scriptaid (3.5 μ g/g mouse, i.p.) clearly inhibits tumor growth in a xenograft mouse model^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!